Administer ENTYVIO as an intravenous infusion over 30 minutes. Do not administer as an intravenous push or bolus. ENTYVIO lyophilized powder must be reconstituted with Sterile Water for injection and diluted in 250 mL of sterile 0.9% Sodium Chloride injection prior to administration [see Reconstitution and Dilution Instructions]. After the infusion is complete, flush with 30 mL of sterile 0.9% Sodium Chloride injection.
ENTYVIO should be administered by a healthcare professional prepared to manage hypersensitivity reactions including  anaphylaxis, if they occur. Appropriate monitoring and medical support measures should be available for immediate use. Observe patients during infusion and until the infusion is complete.
Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current  immunization guidelines.
The recommended dosage of ENTYVIO in adults with ulcerative colitis or Crohn's disease is 300 mg administered by intravenous infusion at zero, two and six weeks and then every eight weeks thereafter.
Discontinue therapy in patients who show no evidence of therapeutic benefit by Week 14.
Reconstitute ENTYVIO at room temperature. ENTYVIO should be reconstituted and prepared by a trained medical professional using aseptic  technique by the following procedure:
Add the 5 mL (300 mg) of reconstituted ENTYVIO solution to 250 mL of sterile 0.9% Sodium Chloride and gently mix the infusion bag. Do not add other medicinal products to the prepared infusion solution or intravenous infusion set. Once reconstituted and diluted, use the infusion solution as soon as possible.
If necessary, the infusion solution may be stored for up to four hours at 2째 to 8째C (36째 to 46째F). Do not freeze. Discard any unused portion of the infusion solution.
